Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vibliome Therapeutics

Request full access

Vibliome Therapeutics is developing a new family of therapeutics for the treatment of cancer, contraception and other indications

Bozeman, United StatesFounded 2017Biotech & Life Sciences

About Vibliome Therapeutics

Vibliome is a biotechnology company specializing in the development of novel Type II kinase inhibitors. These inhibitors are designed to target and lock kinase enzymes in an inactive conformation, which is crucial for regulating cell functions such as metabolism, division, activation, growth, and death. Aberrations in these pathways are often linked to cancer and other chronic diseases. Unlike traditional high-throughput screening methods, Vibliome employs an early profiling strategy against a panel of more than 400 kinase targets, creating a unique structure-activity relationship (SAR) database with over 2,000 compounds. This approach allows for the fine-tuning of selectivity and efficacy in drug development. The company is also focused on developing a PLK4 inhibitor to treat cancers with TRIM37 amplifications, particularly breast cancer. Vibliome's clients primarily include pharmaceutical companies and research institutions looking for advanced solutions in cancer treatment and chronic disease management. The company operates in the biotechnology and pharmaceutical markets, generating revenue through licensing agreements, partnerships, and direct sales of its proprietary inhibitors.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
55.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Feb 2022 $22M $88M Deerfield ↗
EARLY VCEquity / VC Feb 2019 $8M $32M Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Vibliome Therapeutics website traffic

Latest recorded traffic for Vibliome Therapeutics is 160 monthly website visits, down 20% over the last three months. Vibliome Therapeutics's team declined 66.7% over the past year.

Latest monthly visits160 3-month web change-20% 1-year team growth-66.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vibliome Therapeutics in the Bozeman ecosystem

Live from Dealroom

The Vibliome Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Deerfield
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vibliome Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vibliome Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.